- Home
- ASG vs DMAC Comparison
ASG vs DMAC Comparison
Compare ASG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASG
- DMAC
- Stock Information
- Founded
- ASG 1986
- DMAC 2000
- Country
- ASG United States
- DMAC United States
- Employees
- ASG N/A
- DMAC N/A
- Industry
- ASG Investment Managers
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ASG Finance
- DMAC Health Care
- Exchange
- ASG Nasdaq
- DMAC Nasdaq
- Market Cap
- ASG 327.8M
- DMAC 310.1M
- IPO Year
- ASG N/A
- DMAC N/A
- Fundamental
- Price
- ASG $5.60
- DMAC $7.09
- Analyst Decision
- ASG
- DMAC Strong Buy
- Analyst Count
- ASG 0
- DMAC 3
- Target Price
- ASG N/A
- DMAC $12.33
- AVG Volume (30 Days)
- ASG 324.3K
- DMAC 430.9K
- Earning Date
- ASG 01-01-0001
- DMAC 11-12-2025
- Dividend Yield
- ASG 8.09%
- DMAC N/A
- EPS Growth
- ASG N/A
- DMAC N/A
- EPS
- ASG N/A
- DMAC N/A
- Revenue
- ASG N/A
- DMAC N/A
- Revenue This Year
- ASG N/A
- DMAC N/A
- Revenue Next Year
- ASG N/A
- DMAC N/A
- P/E Ratio
- ASG N/A
- DMAC N/A
- Revenue Growth
- ASG N/A
- DMAC N/A
- 52 Week Low
- ASG $4.47
- DMAC $3.19
- 52 Week High
- ASG $5.71
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- ASG 56.50
- DMAC 68.97
- Support Level
- ASG $5.40
- DMAC $6.83
- Resistance Level
- ASG $5.62
- DMAC $7.46
- Average True Range (ATR)
- ASG 0.06
- DMAC 0.41
- MACD
- ASG 0.01
- DMAC 0.11
- Stochastic Oscillator
- ASG 78.08
- DMAC 82.98
About ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.